Align-backed Premier Biotech acquires NexScreen and TransMed
Drug testing company Premier Biotech has bought point-of-care diagnostics provider NexScreen and drug testing supplier TransMed.
Align Capital Partners' portfolio company Premier Biotech announced the acquisitions of NexScreen and TransMed on June 18, 2026. The deals are described as expanding Premier's global footprint and online presence and its product portfolio across healthcare, government and workplace markets.
NexScreen provides point-of-care diagnostic testing to customers in the United States, Australia and New Zealand. TransMed offers a broad catalog of drug testing products and laboratory supplies to more than 1,000 direct customer accounts, supported by an e-commerce platform and an international network of manufacturers, suppliers and resellers. TransMed's owner, Ted Bernhardt, said the company has operated since 2008.
Premier CEO Matt Michalik said NexScreen expands the company's presence in Australia and New Zealand, and that TransMed's catalog and vendor relationships make it a strategic and cultural fit. With these deals, Premier has completed seven acquisitions since partnering with Align Capital Partners in November 2022. The ACP team of Rob Langley, Ervin Cash, Matt Bowen and Sarah Mahosky worked with Premier management on the transactions.
Deal facts
- Target
- NexScreen and TransMed
- Business
- NexScreen provides point-of-care diagnostic testing solutions in the US, Australia and New Zealand. TransMed sells drug testing products and laboratory supplies to more than 1,000 direct accounts through an e-commerce platform.
- Acquirer
- Premier Biotech
- Backed by
- Align Capital Partners
- Seller
- Ted Bernhardt, owner of TransMed
- Deal type
- Add-on
- Status
- Completed
- Announced
- Thursday, June 18, 2026
Sources
- Business WireJun 18, 2026
- Business Wire
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.